Cobimetinib
A targeted cancer therapy that blocks a specific protein (MEK) involved in cell growth signaling pathways. It is often used in combination with other agents to treat certain types of cancer, including melanoma.
Molecular Weight
531.3000 g/mol
LogP
3.90
TPSA
64.60 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.
2D Structure
Cite this structure
Embed this structure
SMILES
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1
InChI
InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1
Molecular Formula
C21H21F3IN3O2
HBD / HBA
3 / 7
Rotatable Bonds
4
Heavy Atoms
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A targeted cancer therapy that blocks a specific protein (MEK) involved in cell growth signaling pathways. It is often used in combination with other agents to treat certain types of cancer, including melanoma.
Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.
Yes, Cobimetinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2146883. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 16222096. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cobimetinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cobimetinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cobimetinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cobimetinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cobimetinib"></drugfyi-drug>